Holen Sie sich die Stockscreener-App
52.02
1.12%
-0.59
Vorhandelsmarkt:
52.15
0.13
+0.25%
Schlusskurs vom Vortag:
$52.61
Offen:
$52.68
24-Stunden-Volumen:
1.10M
Relative Volume:
0.63
Marktkapitalisierung:
$5.12B
Einnahmen:
$4.10M
Nettoeinkommen (Verlust:
$-568.53M
KGV:
-8.3744
EPS:
-6.2118
Netto-Cashflow:
$-401.18M
1W Leistung:
+1.05%
1M Leistung:
+7.46%
6M Leistung:
-7.06%
1J Leistung:
+25.11%
1-Tages-Spanne:
$51.28
$53.27
1-Wochen-Bereich:
$49.02
$53.27
52-Wochen-Spanne:
$42.17
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
52.02 | 5.18B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why is CRISPR Therapeutics (CRSP) down 0.7% since last earnings report? - MSN
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Eastern Progress
Understanding the Setup: (CRSP) and Scalable Risk - Stock Traders Daily
28,037 Shares in CRISPR Therapeutics AG $CRSP Bought by Blue Jean Financial LLC - MarketBeat
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it - MSN
CRISPR Therapeutics stock is absurdly cheap -- here's why analysts see 437% upside potential - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Citizens reiterates CRISPR Therapeutics stock rating on Casgevy data By Investing.com - Investing.com Australia
Citizens reiterates CRISPR Therapeutics stock rating on Casgevy data - Investing.com
CRISPR Therapeutics AG (CRSP) advances but underperforms market: Key facts - MSN
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know - MSN
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts - Yahoo Finance
Why is Crispr Therapeutics stock gaining 3% today? By Investing.com - Investing.com Nigeria
Why is Crispr Therapeutics stock gaining 3% today? - Investing.com UK
Morgan Stanley assumes CRISPR Therapeutics stock with equalweight rating - Investing.com
Morgan Stanley assumes CRISPR Therapeutics stock with equalweight rating By Investing.com - Investing.com Canada
CRSP Stock Quote Price and Forecast - CNN
CRISPR Therapeutics AG Stock 12‑Month Price Target Cut to $81.1, Implies 64% Upside - TradingView
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Norges Bank Buys Shares of 490,206 CRISPR Therapeutics AG $CRSP - MarketBeat
Amova Asset Management Americas Inc. Sells 205,564 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan
Director at CRISPR (CRSP) receives 13,000-share stock option grant - Stock Titan
CRISPR Therapeutics (CRSP) director granted 13,000 options at $51.84 strike - Stock Titan
CRISPR Therapeutics (CRSP) director awarded 13,000-share stock option grant - Stock Titan
Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - AOL.com
CRISPR Therapeutics stock (CH0334081137): Gene-editing hopes after recent updates on exa-cel and pip - AD HOC NEWS
CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline - Intellectia AI
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? - The Motley Fool
Eli Lilly just proved gene editing could be pharma's next gold rush -- but CRISPR Therapeutics investors should watch out - MSN
Contrarius Group Holdings Ltd Has $8.21 Million Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Capital International Investors Increases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next - simplywall.st
A Look At CRISPR Therapeutics (CRSP) Valuation After Casgevy Launch And Ongoing Gene Editing Pipeline Progress - Sahm
Geode Capital Management LLC Boosts Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline - Insider Monkey
CRISPR Therapeutics stock (CH0334081137): Q1 loss and gene-editing focus shape valuation picture - AD HOC NEWS
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRISPR Therapeutics AG Amends and Restates Articles of Association – Key Updates and Company Information - Minichart
Transcript : CRISPR Therapeutics AG Presents at 46th Annual William Blair Growth Stock Conference, Jun-03-2026 04 - marketscreener.com
CRISPR Therapeutics (NASDAQ: CRSP) investors approve 2026 plan and capital changes - Stock Titan
CRISPR Therapeutics Jumps 12% in New York Trading - TechStock²
CRSP Stock Climbs As Wall Street Lifts Price Targets - StocksToTrade
Stock Traders Buy High Volume of CRISPR Therapeutics Call Options (NASDAQ:CRSP) - MarketBeat
CRSP Stock Climbs As Wall Street Nudges Price Targets Higher - timothysykes.com
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crispr Therapeutics Ag-Aktie (CRSP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 23 '26 |
Sale |
46.78 |
3,182 |
148,854 |
94,308 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 23 '26 |
Sale |
46.78 |
10,020 |
468,736 |
255,501 |
| Prasad Raju | Chief Financial Officer |
Mar 23 '26 |
Sale |
46.78 |
3,708 |
173,460 |
15,565 |
| Patel Naimish | Chief Medical Officer |
Mar 16 '26 |
Sale |
48.26 |
3,150 |
152,019 |
13,143 |
| Prasad Raju | Chief Financial Officer |
Mar 16 '26 |
Sale |
48.26 |
9,869 |
476,278 |
13,773 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 16 '26 |
Sale |
48.26 |
3,450 |
166,497 |
91,240 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 16 '26 |
Sale |
48.26 |
10,349 |
499,443 |
245,834 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '26 |
Sale |
52.80 |
2,800 |
147,840 |
87,815 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '26 |
Sale |
52.80 |
9,798 |
517,334 |
235,558 |
| Kulkarni Samarth | Chief Executive Officer |
Feb 19 '26 |
Sale |
52.58 |
6,967 |
366,325 |
226,106 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):